PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
18606716-5	2008	Suppression of osteoclastogenesis through RANKL inhibition may enhance the effects of docetaxel on skeletal tumors.	Docetaxel	86-95	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	42-47	
19082914-10	2009	RANKL mRNA expression induced by 1,25-dihydroxyvitamin D(3) plus prostaglandin E(2) in osteoblasts was not affected by docetaxel even at 10(-6) M. Docetaxel at 10(-6) M, but not at 10(-8) M, inhibited pit-forming activity of osteoclasts cultured on dentine.	Docetaxel	147-156	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	0-5	
18606716-11	2008	RANKL inhibition may enhance docetaxel effects by increasing tumor cell apoptosis as evident by increased active caspase-3.	Docetaxel	29-38	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	0-5	
18606716-12	2008	These studies show that inhibition of RANKL provides an additive benefit to docetaxel treatment in a murine model of prostate cancer bone metastasis and supports clinical evaluation of this treatment option in patients.	Docetaxel	76-85	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	38-43	
18324676-0	2008	RANKL inhibition is an effective adjuvant for docetaxel in a prostate cancer bone metastases model.	Docetaxel	46-55	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	0-5	
18324676-6	2008	METHODS: The efficacy of inhibiting RANKL, using a recombinant soluble RANK extracellular domain fused with the immunoglobulin Fc domain (RANK-Fc), was tested as an adjuvant therapy with docetaxel for PCa bone metastasis in a murine intra-tibial model.	Docetaxel	187-196	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	36-41